A new antiangiogenic C24 oxylipin from the soft coral Sinularia numerosa

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 6, 2009, Pages 2181-2184

  Yamashita, Takahiro ^a   Nakao, Yoichi ^a,b   Matsunaga, Shigeki ^a   Oikawa, Tsutomu ^c   Imahara, Yukimitsu ^d   Fusetani, Nobuhiro ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c KANAGAWA UNIVERSITY OF HUMAN SERVICES   (Japan)

^d Kainan   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Angiogenesis inhibitor; Marine natural products; Oxylipin; Tube formation

Indexed keywords

15 HYDROXYTETRACOSA 6,9,12,16,18 PENTAENOIC ACID; ANGIOGENESIS INHIBITOR; CIGLITAZONE; LEUKOTRIENE B4; OXYLIPIN; PIRINIXIC ACID; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORAL; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; SINULARIA NUMEROSA; STRUCTURE ANALYSIS; ANIMAL; ANTHOZOA; CHEMICAL STRUCTURE; CHEMISTRY; ISOLATION AND PURIFICATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ALCYONACEA; SINULARIA NUMEROSA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTHOZOA; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OXYLIPINS;

EID: 62149148140     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.10.083     Document Type: Article

References (17)

1. Folkman J., and Klagsbrun M. Science 234 (1987) 444
2. Weidner N., Semple J.P., and Weigh W.R. N. Engl. J. Med. 324 (1991) 1
3. Keeding V.L., and Sandler A.B. Cancer Sci. 98 (2007) 1825
4. Hofmeister V., Schrama D., and Becker J.C. Cancer Immunol. Immunother. 57 (2008) 1
5. Folkman J., Langer R., Linhardt R.J., Haudenschild C., and Taylor S. Science 221 (1983) 719
6. Oikawa T., Sasaki T., Nakamura M., Shimamura M., Tanahashi N., Omura S., and Tanaka K. Biochem. Biophys. Res. Commun. 246 (1998) 243
7. EA.hy 926 cell line was established by fusing HUVECs (human umbilical vein endothelial cells) with the permanent cell line A 549 (derived from a human lung carcinoma). It was kindly provided by Dr. Cora Jean S. Edgell (University of North Carolina, Department of Pathology, 7525 Chapel Hill, NC 27599, USA).
8. Edgell C.J.S., McDonald C.C., and Graham J.B. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 3734
9. Kupchan S.M., Britton R.W., Ziegler M.F., and Sigel C.W. J. Org. Chem. 38 (1973) 178
10. Breitmaier E., and Voelter W. Carbon-13 NMR spectroscopy. 3rd ed. (1989), VCH, New York pp 192-194
11. Ortega M.J., Zubia E., Sanchez M.C., Salva J., and Carballo J.L. Tetrahedron 60 (2004) 2517
12. Tube-formation assay was performed at six concentrations (1-40 μg/mL) of 11-HETE (2) and inhibition was observed at 20 and 40 μg/mL. As for 9-hydroxy-octadeca-6,10,12-trienoic acid (9-HOTE; 3), detailed evaluation of inhibitory activity was not possible because of the scarce amount of the purified compound. Inhibitory activity at 20 μg/mL was observed for the fraction mainly containing compound 3. Commercially available related 9-hydroxy-octadeca-6,10,12-dienoic acid (9-HODE), as well as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid was evaluated for inhibitory activity against tube formation. Inhibition was observed for 9-HODE at 25 μM, while no remarkable inhibition was observed for DHA, EPA, or arachidonic acid at 50 μM.
13. Mezentsev A., Seta F., Dunn M.W., Ono N., Falck J.R., and Laniado-Schwartzman M. J. Biol. Chem. 277 (2002) 18670
14. Xin X., Yang S., Kowalski J., and Gerritsen M.E. J. Biol. Chem. 274 (1999) 9116
15. Meissner M., Stein M., Urbich C., Reisinger K., Suske G., Staels B., Kaufmann R., and Gille J. Circ. Res. 94 (2004) 324
16. Fukushi J., Ono M., Morikawa W., Iwamoto Y., and Kuwano M. J. Immunol. 165 (2000) 2818
17. Rival Y., Benéteau N., Taillander T., Pezet M., Dupont-Passelaigue E., Patoiseau J.-F., Junquéro D., Colpaert F.C., and Delhon A. Eur. J. Pharmacol. 435 (2002) 143